Open AccessPhospholipase Cβ3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain
Author(s) -
Tiejun Shi,
Su-Xing Leslie Liu,
Henrik Hammarberg,
Masahiko Watanabe,
ZhiQing David Xu,
Tomas Hökfelt
Publication year - 2008
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.0810899105
Subject(s) - neuropathic pain , spinal cord , phospholipase c , medicine , dorsum , neuroscience , anesthesia , dorsal root ganglion , pharmacology , biology , anatomy , receptor
Treatment of neuropathic pain is a major clinical problem. This study shows expression of phospholipase ß3 (PLCß3) in mouse and human DRG neurons, mainly in small ones and mostly with a nonpeptidergic phenotype. After spared nerve injury, the pain threshold was strongly reduced, and systemic treatment of such animals with the unselective PLC inhibitor U73122 caused a rapid and long-lasting (48-h) increase in pain threshold. Thus, inhibition of PLC may provide a way to treat neuropathic pain.